The Spontaneous Incidence of Neurological Clinical Signs in Preclinical Species Using Cage-side Observations or High-definition Video Monitoring: A Retrospective Analysis
Abstract
When conducting toxicology studies, the interpretation of drug-related neurological clinical signs such as convulsions, myoclonus/myoclonic jerks, tremors, ataxia, and salivation requires an understanding of the spontaneous incidence of those observations in commonly used laboratory animal species. The spontaneous incidence of central nervous system clinical signs in control animals from a single facility using cage-side observations or high definition video monitoring was retrospectively analyzed. Spontaneous convulsions were observed at low incidence in Beagle dogs and Sprague–Dawley rats but were not identified in cynomolgus monkeys and Göttingen minipigs. Spontaneous myoclonic jerks and muscle twitches were observed at low incidence in Beagle dogs, cynomolgus monkeys, and Sprague–Dawley rats but were not seen in Göttingen minipigs. Spontaneous ataxia/incoordination was identified in all species and generally with a higher incidence when using video monitoring. Salivation and tremors were the two most frequent spontaneous clinical signs and both were observed in all species. Data from the current study unveil potential limitations when using control data obtained from a single study for toxicology interpretation related to low incidence neurological clinical signs while providing historical control data from Beagle dogs, cynomolgus monkeys, Sprague–Dawley rats, and Göttingen minipigs.
Get full access to this article
View all access and purchase options for this article.
References
1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801.
2. FDA. Toxicological Principles for the safety assessment of food ingredients. Chapter IV.C.10. Neurotoxicity studies. In: Nutrition CoFSaA, ed. Redbook 2000; 2000.
3. Authier S, Arezzo J, Delatte MS, et al. Safety pharmacology investigations on the nervous system: an industry survey. J Pharmacol Toxicol Methods. 2016;81:37-46.
4. Shulman MB, Barr W. Treatment of memory disorders in epilepsy. Epilepsy Behav. 2002;3(5):30-34.
5. Löscher W, Czuczwar SJ. Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy. Eur J Pharmacol. 1986;128(1-2):55-65.
6. Takayama S, Hirohashi M, Kato M, Shimada H. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health. 1995;45(1):1-45.
7. Essig CF. Barbiturate withdrawal in white rats. Int J Neuropharmacol. 1966;5(1):103-107.
8. West R, Gossop M. Overview: a comparison of withdrawal symptoms from different drug classes. Addiction. 1994;89(11):1483-1489.
9. Moser P, Wolinsky T, Castagné V, Duxon M. Current approaches and issues in non-clinical evaluation of abuse and dependence. J Pharmacol Toxicol Methods. 2011;63(2):160-167.
10. Classification Co, Epilepsy TotILA. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22(4):489-501.
11. Deuschl G, Bain P, Brin M, Committee AHS. Consensus statement of the movement disorder society on tremor. Mov Disord. 1998;13(S3):2-23.
12. Valls-Solé J, Montero J. Role of EMG evaluation in muscle hyperactivity syndromes. Jf Neurol. 2004;251:251-260.
13. Troxel MT, Drobatz KJ, Vite CH. Signs of neurologic dysfunction in dogs with central versus peripheral vestibular disease. J Am Vet Med Assoc. 2005;227(4):570-574.
14. Crawford PF III, Zimmerman EE. Differentiation and diagnosis of tremor. Am Fam Physician. 2011;83(6):697-702.
15. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4(1):47-62.
16. Janssen S, Bloem BR, van de Warrenburg BP. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017;264(8):1559-1566.
17. Van Gaalen J, Kerstens F, Maas R, Härmark L, van de Warrenburg B. Drug-induced cerebellar ataxia: a systematic review. CNS Drugs. 2014;28:1139-1153.
18. Berendt M, Farquhar RG, Mandigers PJ, et al. International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Vet Res. 2015;11(1):1-11.
19. Cerda-Gonzalez S, Packer RA, Garosi L, et al. International veterinary canine dyskinesia task force ECVN consensus statement: terminology and classification. J Vet Intern Med. 2021;35(3):1218-1230.
20. Fentener van Vlissingen J, Borrens M, Girod A, Lelovas P, Morrison F, Torres YS. The reporting of clinical signs in laboratory animals: FELASA working group report. Laboratory animals. 2015;49(4):267-283.
21. Podell M. Seizures. In: BSAVA Manual of Canine and Feline Neurology; 2013:117-135.
22. Accardi MV, Huang H, Authier S. Seizure liability assessments using the hippocampal tissue slice: comparison of non-clinical species. J Pharmacol Toxicol Methods. 2018;93:59-68.
23. Authier S, Accardi MV, Paquette D, et al. Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys. J Pharmacol Toxicol Methods. 2016;81:306-312.
24. Bassett L, Troncy E, Pouliot M, Paquette D, Ascah A, Authier S. Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: methods in follow-up safety pharmacology seizure liability assessments. J Pharmacol Toxicol Methods. 2014;70(3):230-240.
25. Lowrie M, Garosi L. Classification of involuntary movements in dogs: tremors and twitches. Vet J. 2016;214:109-116.
26. Lowrie M, Garosi L. Classification of involuntary movements in dogs: myoclonus and myotonia. J Vet Intern Med. 2017;31(4):979-987.
27. Kosmal A, Stepniewska I, Markow G. Laminar organization of efferent connections of the prefrontal cortex in the dog. Acta Neurobiol Exp. 1983;43(2):115-127.
28. Abdo WF, Van De Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol. 2010;6(1):29-37.
29. Berendt M, Gram L. Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. J Vet Intern Med. 1999;13(1):14-20.
30. Scaramelli A, Braga P, Avellanal A, et al. Prodromal symptoms in epileptic patients: clinical characterization of the pre-ictal phase. Seizure. 2009;18(4):246-250.
31. Kelly KM, Kharlamov A, Hentosz TM, et al. Photothrombotic brain infarction results in seizure activity in aging Fischer 344 and Sprague Dawley rats. Epilepsy Res. 2001;47(3):189-203.
32. Wiest MC, Nicolelis MA. Behavioral detection of tactile stimuli during 7–12 Hz cortical oscillations in awake rats. Nat Neurosci. 2003;6(9):913-914.
33. Pearce PS, Friedman D, LaFrancois JJ, et al. Spike–wave discharges in adult Sprague–Dawley rats and their implications for animal models of temporal lobe epilepsy. Epilepsy Behav. 2014;32:121-131.
34. Higashino A, Osada N, Suto Y, et al. Development of an integrative database with 499 novel microsatellite markers for Macaca fascicularis. BMC Genet. 2009;10:1-6.
35. Watanabe A, Shiina T, Shimizu S, et al. A BAC-based contig map of the cynomolgus macaque (Macaca fascicularis) major histocompatibility complex genomic region. Genomics. 2007;89(3):402-412.
36. Markgraf CG, DeBoer EM, Cirino M. EEG in monkey but not rat indentifies seizure potential of a pharmaceutical development candidate. J Pharmacol Toxicol Methods. 2010;2(62):e41-e42.
37. Lind NM, Moustgaard A, Jelsing J, Vajta G, Cumming P, Hansen AK. The use of pigs in neuroscience: modeling brain disorders. Neurosci Biobehav Rev. 2007;31(5):728-751.
38. Parent JM. Clinical management of canine seizures. Vet Clin North Am: Small Anim Pract. 1988;18(3):605-622.
39. Heynold Y, Faissler D, Steffen F, Jaggy A. Clinical, epidemiological and treatment results of idiopathic epilepsy in 54 Labrador retrievers: a long-term study. J Small Anim Pract. 1997;38(1):7-14.
40. Podell M. Seizures in dogs. Vet Clin North Am Small Anim Pract. 1996;26(4):779-809.
41. Shell LG. The diagnostic approach to seizures. Vet Med. 1993;88:641-646.
42. Kathmann I, Jaggy A, Busato A, Bärtschi M, Gaillard C. Clinical and genetic investigations of idiopathic epilepsy in the Bernese mountain dog. J Small Anim Pract. 1999;40(7):319-325.
43. Authier S, Arezzo J, Pouliot M, et al. EEG: characteristics of drug-induced seizures in rats, dogs and non-human primates. J Pharmacol Toxicol Methods. 2019;97:52-58.
44. Koutinas F, Polyzopoulou S, Kontos V. Clinical and clinicopathologic evaluation in 14 dogs with presumed idiopathic epilepsy. Deltion tis Ellinikis Ktiniatrikis Etaireias (Greece). 1994.
45. Thomas WB. Managing epileptic dogs. Compend Continuing Educ Pract Vet. 1994;16(12):1573-1580.
46. Jaggy A, Faissler D, Gaillard C, Srenk P, Graber H. Genetic aspects of idiopathic epilepsy in Labrador retrievers. J Small Anim Pract. 1998;39(6):275-280.
47. Jokinen T, Metsähonkala L, Bergamasco L, et al. Benign familial juvenile epilepsy in Lagotto Romagnolo dogs. J Vet Intern Med. 2007;21(3):464-471.
48. Seppälä EH, Koskinen LL, Gulløv CH, et al. Identification of a novel idiopathic epilepsy locus in Belgian Shepherd dogs. PLoS One. 2012;7(3):e33549.
49. Seppälä EH, Jokinen TS, Fukata M, et al. LGI2 truncation causes a remitting focal epilepsy in dogs. PLoS Genet. 2011;7(7):e1002194.
50. Scheffer IE, Berkovic SF. The genetics of human epilepsy. Trends pharmacol Sci. 2003;24(8):428-433.
51. Steinlein OK. Genes and mutations in human idiopathic epilepsy. Brain Dev. 2004;26(4):213-218.
52. Satomoto K, Kuroiwa Y, Masubuchi Y, Uemura H, Oshima Y, Okazaki S. Spontaneous convulsions in Sprague-Dawley rats in carcinogenicity studies. J Toxicol Sci. 2012;37(3):645-647.
53. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med. 2002;22(3):235-239.
54. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016;81(3):412-419.
55. Lohi H, Young EJ, Fitzmaurice SN, et al. Expanded repeat in canine epilepsy. Science. 2005;307(5706):81-81.
56. Hajek I, Kettner F, Simerdova V, et al. NHLRC1 repeat expansion in two beagles with Lafora disease. J Small Anim Pract. 2016;57(11):650-652.
57. Minassian BA, Lee JR, Herbrick J-A, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20(2):171-174.
58. Chan E, Bulman D, Paterson A, et al. Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet. 2003;40(9):671-675.
59. Gómez-Abad C, Gómez-Garre P, Gutiérrez-Delicado E, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology. 2005;64(6):982-986.
60. Carskadon MA, Rechtschaffen A. Monitoring and staging human sleep. Principles and Pract Sleep Med. 2011;5:16-26.
61. Authier S, Bassett L, Pouliot M, et al. Reprint of “Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in Cynomolgus monkeys”. J Pharmacol Toxicol Methods. 2014;70(3):287-294.
62. Brefel-Courbon C, Gardette V, Ory F, Montastruc J. Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin/Clin Neurophysiol. 2006;36(5-6):333-336.
63. De Lahunta A, Glass EN, Kent M. de Lahunta’s Veterinary Neuroanatomy and Clinical Neurology-E-Book. Elsevier Health Sciences; 2020.
64. Benito-León J, Labiano-Fontcuberta A. Linking essential tremor to the cerebellum: clinical evidence. Cerebellum. 2016;15:253-262.
65. Sargan DR. IDID: inherited diseases in dogs: web-based information for canine inherited disease genetics. Mamm Genome. 2004;15:503-506.
66. De Lahunta A, Glass EN, Kent M. Veterinary Neuroanatomy and Clinical Neurology-E-Book. Elsevier Health Sciences; 2014.
67. Wolf M, Bruehschwein A, Sauter-Louis C, Sewell AC, Fischer A. An inherited episodic head tremor syndrome in Doberman pinscher dogs. Mov Disord. 2011;26(13):2381-2386.
68. Guevar J, De Decker S, Van Ham LM, Fischer A, Volk HA. Idiopathic head tremor in English bulldogs. Mov Disord. 2014;29(2):191-194.
69. Shell LG, Berezowski J, Rishniw M, Nibblett BM, Kelly P. Clinical and breed characteristics of idiopathic head tremor syndrome in 291 dogs: a retrospective study. Vet Med Int. 2015;2015: 65463.
70. van de Wardt J, van der Stouwe AM, Dirkx M, et al. Systematic clinical approach for diagnosing upper limb tremor. J Neurol Neurosurg Psychiatr. 2020;91(8):822-830.
71. Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. J Neurol Sci. 2022;435:120192.
72. Urkasemsin G, Olby NJ. Canine hereditary ataxia. Vet Clin Small Anim Pract. 2014;44(6):1075-1089.
73. Rossmeisl JH. Vestibular disease in dogs and cats. Vet Clin Small Anim Pract. 2010;40(1):81-100.
74. Kent M, Platt SR, Schatzberg SJ. The neurology of balance: function and dysfunction of the vestibular system in dogs and cats. Vet J. 2010;185(3):247-258.
75. Thomas WB. Vestibular dysfunction. Veterinary clinics of north america: small animal practice. 2000;30(1):227-249.
76. Sanders SG, Bagley RS. Disorders of hearing and balance: the vestibulocochlear nerve (CN VIII) and associated structures. In: A Practical Guide to Canine and Feline Neurology; 2003.
77. Schunk K. Diseases of the vestibular system. Prog Vet Neurol. 1990;1(3):247-254.
78. Forman OP, De Risio L, Stewart J, Mellersh CS, Beltran E. Genome-wide mRNA sequencing of a single canine cerebellar cortical degeneration case leads to the identification of a disease associated SPTBN2 mutation. BMC Genet. 2012;13(1):1-11.
79. agueny A. Cramp-fasciculation syndrome. Rev Neurol. 2005;161(12P1):1260-1266.
80. Vanhaesebrouck AE, Bhatti SF, Franklin RJ, Van Ham L. Myokymia and neuromyotonia in veterinary medicine: a comparison with peripheral nerve hyperexcitability syndrome in humans. Vet J. 2013;197(2):153-162.
81. Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet. 1994;8(2):136-140.
82. Wuttke TV, Jurkat-Rott K, Paulus W, Garncarek M, Lehmann-Horn F, Lerche H. Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology. 2007;69(22):2045-2053.
83. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125(8):1887-1895.
84. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-2748.
85. Arroyo EJ, Xu Y-T, Zhou L, et al. Myelinating schwann cells determine the internodal localization of Kv1. 1, Kv1. 2, Kvβ2, and Caspr. J Neurocytol. 1999;28:333-347.
86. Vanhaesebrouck A, Van Soens I, Poncelet L, et al. Clinical and electrophysiological characterization of myokymia and neuromyotonia in Jack Russell Terriers. J Vet Intern Med. 2010;24(4):882-889.
87. Pakozdy A, Halasz P, Klang A, et al. Suspected limbic encephalitis and seizure in cats associated with voltage-gated potassium channel (VGKC) complex antibody. J Vet Intern Med. 2013;27(1):212-214.
88. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farré M. Salivary secretory disorders, inducing drugs, and clinical management. Int J Med Sci. 2015;12(10):811.
89. Kook PH. Ptyalism in dogs and cats-a short review. North American Veterinary Conference, Orlando, US, 19-23 January 2013.
90. Jarius S, Wildemann B. And Pavlov still rings a bell: summarising the evidence for the use of a bell in Pavlov’s iconic experiments on classical conditioning. J Neurol. 2015;262:2177-2178.
91. Satya-Murti S, Lockhart J. Recognizing and reducing cognitive bias in clinical and forensic neurology. Neurol Clin Pract. 2015;5(5):389-396.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: December 8, 2023
Issue published: March/April 2024
Keywords
PubMed: 38063479
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in International Journal of Toxicology.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 158
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 0
There are no citing articles to show.
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
ACT members can access this journal content using society membership credentials.
ACT members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
